药学学报, 2019, 54(4): 645-652
引用本文:
饶志, 张帆, 张国强, 马彦荣, 周燕, 武新安, 秦红岩, 魏玉辉. 应用优化高胆红素HepaRG细胞模型筛选茵栀黄含药血清中的潜在药效物质[J]. 药学学报, 2019, 54(4): 645-652.
RAO Zhi, ZHANG Fan, ZHANG Guo-qiang, MA Yan-rong, ZHOU Yan, WU Xin-an, QIN Hong-yan, WEI Yu-hui. Screening for potential bioactive components of Yin-zhi-huang using high bilirubin HepaRG cells incubating with serum from animals[J]. Acta Pharmaceutica Sinica, 2019, 54(4): 645-652.

应用优化高胆红素HepaRG细胞模型筛选茵栀黄含药血清中的潜在药效物质
饶志, 张帆, 张国强, 马彦荣, 周燕, 武新安, 秦红岩, 魏玉辉
兰州大学第一医院药剂科, 甘肃 兰州 730000
摘要:
本研究建立了一种优化的高胆红素细胞模型,以模拟人体黄疸病理状态,并进行细胞水平的茵栀黄药效物质筛选。用胆红素及丙磺舒共同孵育HepaRG细胞建立细胞模型;收集给予茵栀黄注射液后大鼠含药血清,测定经此含药血清干预后细胞内总胆红素、间接胆红素及细胞外直接胆红素含量;应用LC-MS/MS的动态多反应监测技术测定茵栀黄注射液中的复杂药物成分,并检测含药血清孵育后与HepaRG细胞结合(或进入细胞内)的药物组分。本研究动物实验遵守兰州大学第一医院伦理委员会规程。结果显示,经40 μg·mL-1胆红素及50 μg·mL-1丙磺舒共同孵育可建立48 h内稳定的高胆红素HepaRG细胞模型;本研究证实,茵栀黄注射液孵育高胆红素细胞模型后,细胞内总胆红素及间接胆红素含量可分别降低52.4%及60.1%,而细胞外直接胆红素含量可升高52.5%。DMRM模式可对53种药物成分进行测定,经含药血清孵育HepaRG细胞系后可从中筛选出8种潜在药效物质。本研究发现茵栀黄注射液在高胆红素细胞模型中具有显著退黄作用,应用本方法可成功筛选出茵栀黄注射液进入靶细胞内发挥作用的潜在药效物质。该方法简单、高效、灵敏、特异,可为中药药效物质的高通量筛选提供一种新的研究思路。
关键词:    高胆红素      HepaRG细胞      动态多反应监测      茵栀黄      药效物质     
Screening for potential bioactive components of Yin-zhi-huang using high bilirubin HepaRG cells incubating with serum from animals
RAO Zhi, ZHANG Fan, ZHANG Guo-qiang, MA Yan-rong, ZHOU Yan, WU Xin-an, QIN Hong-yan, WEI Yu-hui
Pharmacy Department, The First Hospital of Lanzhou University, Lanzhou 730000, China
Abstract:
A hyper-bilirubin cell model was established for its relevance to the pathological state of jaundice in human. This model was used to screen for the pharmacological components of Yin-Zhi-huang (YZH). Total bilirubin, indirect bilirubin in cells, and direct bilirubin in extracellular fluid were quantified after HepaRG cells were incubated with serum from rats injected with multiple components of YZH. Cellular uptake was determined by dynamic multiple reaction monitoring (DMRM) using LC-MS/MS. We found that the stable hyper-bilirubin HepaRG cell model could be established by incubating cells with 40 μg·mL-1 bilirubin and 50 μg·mL-1 probenecid. When the hyper-bilirubin cell model was incubated with serum from rats of YZH injection, there were 52.4% and 60.1% decrease in intercellular total bilirubin and indirect bilirubin, respectively, and 52.5% increase in extracellular direct bilirubin. Using DMRM mode, 53 components could be determined, and 8 potential bioactive candidates were identified from the serum. This method could be used to screen for bioactive metabolites of YZH. This strategy is simple, highly active, sensitive and specific, providing a new method for high throughput screening of therapeutic or toxic metabolites from traditional Chinese medicine. The regulations of Ethics Committee in the First Hospital of Lanzhou University were abided in the rat experiment of this study.
Key words:    high bilirubin    HepaRG cell    dynamic multiple reaction monitoring    Yin-zhi-huang    pharmacological substance   
收稿日期: 2018-10-11
DOI: 10.16438/j.0513-4870.2018-0928
基金项目: 国家自然科学基金资助项目(81373927,81241110).
通讯作者: 魏玉辉
Email: pharm_ldyy@163.com
相关功能
PDF(518KB) Free
打印本文
0
作者相关文章
饶志  在本刊中的所有文章
张帆  在本刊中的所有文章
张国强  在本刊中的所有文章
马彦荣  在本刊中的所有文章
周燕  在本刊中的所有文章
武新安  在本刊中的所有文章
秦红岩  在本刊中的所有文章
魏玉辉  在本刊中的所有文章

参考文献:
[1] Rao Z, Qin HY, Wei YH, et al. Development of a dynamic multiple reaction monitoring method for determination of digoxin and six active components of Ginkgo biloba leaf extract in rat plasma[J]. J Chromatogr B, 2014, 959:27-35.
[2] Dong W, Hao XJ, Wang CZ, et al. Serum pharmacochemistry of honey-fried Stemona tuberosa Lour. by UHPLC-QTOF/MS and MetaboLynx analysi[J]. Acta Pharm Sin (药学学报), 2016, 51:1458-1463.
[3] Qi LW, Zhou JL, Hao HP, et al. Biological-chemical profiling of in vitro and in vivo bioactive compounds from traditional Chinese medicines with holistic views[J]. J China Pharm Univ (中国药科大学学报), 2010, 41:195-202.
[4] Li SL, Li P, Sheng LH, et al. Live cell extraction and HPLC-MS analysis for predicting bioactive components of traditional Chinese medicines[J]. J Pharm Biomed Anal, 2006, 41:576-581.
[5] Chen Z, Zhang L, Zeng L, et al. Probiotics supplementation therapy for pathological neonatal jaundice:a systematic review and meta-analysis[J]. Front Pharmacol, 2017, 8:432.
[6] Ziberna L, Martelanc M, Franko M, et al. Bilirubin is an endogenous antioxidant in human vascular endotheial cells[J]. Sci Rep, 2016, 6:29240.
[7] Yamaza H, Sonoda S, Nonaka K, et al. Pamidronate decreases bilirubin-impaired cell death and improves dentinogenic dysfunction of stem cells from human deciduous teeth[J]. Stem Cell Res Ther, 2018, 9:303.
[8] Du Y, Li X, Lv X, et al. Highly sensitive and selective sensing of free bilirubin using metal-organic frameworks-based energy transfer processes[J]. ACS Appl Mater Interfaces, 2017, 9:30925-30932.
[9] Yan J, Xie G, Liang C, et al. Herbal medicine Yinchenhaotang protects against α-naphthylisothiocyanate-induced cholestasis in rats[J]. Sci Rep, 2017, 7:4211.
[10] Dilektasi E, Ozmen NM, Gundogdu E, et al. The effects of obstructive jaundice on the brain:an experimental study[J]. Asian J Surg, 2016, 39:155-163.
[11] Turk O, Badak B, Ates E, et al. The role of growth factors on hepatic damage in rats with obstructive jaundice[J]. Springer Plus, 2016, 5:1274.
[12] Keppler D. The roles of MRP2, MRP3, OATP1B1 and OATP1B3 in conjugated hyperbilirubinemia[J]. Drug Metab Dispos, 2014, 42:561-565.
[13] Liu ZH, Liu KX. The transporters of intestinal tract and their study methods[J]. Acta Pharm Sin (药学学报), 2011, 46:370-376.
[14] Wu RH, Feng S, Han M, et al. Yinzhihuang oral liquid combined with phototherapy for neonatal jaundice:a systematic review and meta-analysis of randomized clinical trials[J]. BMC Complement Altern Med, 2018, 18:228.
[15] Zhang GQ, Zhou Y, Rao Z, et al. Effect of Yin-Zhi-Huang on up-regulation of Oatp2, Ntcp, and Mrp2 proteins in estrogen-induced rat cholestasis[J]. Pharma Biol, 2015, 53:319-325.
[16] Rao Z, Zhang F, Zhang XY, et al. Multicomponent determination of traditional Chinese medicine preparation yin-zhi-huang injection by LC-MS/MS for screening of its potential bioactive candidates using HepaRG cells[J]. Biomed Chromatogr, 2018. DOI:10.1002/bmc.4057.